Lasmiditan: A New Drug for Acute Migraine

Author Details

Ardra. P.K, Kavya Prathap, Sherin M Saji, Irene Thomas, Ansa Mathew

Journal Details


Published: 16 December 2019 | Article Type :


In related to the increased risk of cardio vascular (CV) diseases associated with migraine, there is a interest in the development of a new drug in the treatment of acute migraine which selectively act on non-vascular targets. Existing treatments are limited due to contra indications, or patient avoidance of side effects. This analysis show that 5-HT1F agonist have shown improved results in the treatment of migraine head ache. Also indicated the safety and efficacy of oral lasmiditan, a selective serotonin 5-hydroxytryptamine 1F receptor agonist in the migraine treatment. Research suggests that lasmiditan lacks vasoconstrictive properties and may be a safe and effective treatment in patients refractory to the acute migraine medications compared to the currently used drugs for migraine.1

Keywords: lasmiditan, 5HT-1F, migraine, headache, serotonin

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright © Author(s) retain the copyright of this article.




Volume & Issue

Article Type

How to Cite


Ardra. P.K, Kavya Prathap, Sherin M Saji, Irene Thomas, Ansa Mathew. (2019-12-16). "Lasmiditan: A New Drug for Acute Migraine." *Volume 2*, 1, 16-20